Tanya T. Behnan

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, Cancer.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Traci M. Blonquist, D. Neuberg, K. Ballen, 2018, Cancer.